Prnewswire
NEW YORK, March 9, 2011 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:
Cancer Vaccines – Pipeline Assessment and Market Forecasts to 2017
http://www.reportlinker.com/p0312154/Cancer-Vaccines—Pipeline-Assessment-and-Market-Forecasts-to-2017.html
Cancer Vaccines – Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist’s new report, “Cancer Vaccines – Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global Cancer vaccines market. The report identifies key trends shaping and driving the global Atopic dermatitis disease market. It also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cancer vaccines sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research, and in house analysis by GlobalData’s team of industry experts.
GlobalData has estimated that the global cancer vaccines market in 2009 was worth $1.8 billion. There are currently two products, which constitute the global cancer vaccines market. These are Gardasil and Cervarix used for the treatment of cervical cancer. Oncophage has also been approved for kidney cancer but only in Russia. Hence the market forecasts do not include this vaccine. The present pipeline for cancer vaccines seems to be very promising with numerous molecules present in the Phase II and III stages. From the market perspective, there are going to be multiple launches of vaccines between 2010 and 2013-14, which would substantially increase the market size and growth. The cost of three complete dose courses of the vaccines ranges approximately from $380 to $400.
The cancer vaccines developmental pipeline is strong with about 239 products in various phases of clinical development including 21 molecules in Phase III. The Phase III pipeline activity is strong. It mainly consists of clinical studies involving antigen/adjuvant vaccines regimen. The Phase III pipeline contains some novel therapeutic vaccines. These options are also present in the Phase II stage pipeline. With all these factors, it is likely that the options in the pipeline will cause a dramatic change to the market in the near future and the market activity will primarily be dominated by the molecules in the Phase II and Phase I pipeline.
Leave a Reply